Clinical research continues to struggle with a lack of representation within trial populations, and gender diversity in clinical trials remains a critical issue.
AI and wearable medical devices are already advancing patient care, and transformative use of data and digital innovation is set to enable a new generation of medicines, faster.
In this penultimate instalment of the five-part, festive series of the pharmaphorum podcast, host Nicole Raleigh speaks with Bobby Savarese, senior principal and business development direct
EVERSANA’s alliance with Amazon Web Services (AWS) on the application of generative artificial intelligence (GenAI) to the pharma sector has borne its first fruit – a new
Owlstone Medical has secured a $5 million equity investment and initial $1.5 million grant funding, committed by the Bill and Melinda Gates Foundation, for development of
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.